

**REMARKS/ARGUMENTS**

Applicants respectfully request entry of this amendment.


The amendment to the title is made to more clearly describe the subject matter of the instant application and adds no new matter.

The amendments to the specification merely correct errors in the Japanese specification, which would be apparent to one skilled in the relevant art, from other descriptions in the specification or from common technical knowledge. In particular, paragraph 12 is amended from "dichlorotriazine isothiocyanate" to "dichlorotriazine fluorescein". One of skill in the art would recognize that there is no compound "dichlorotriazine isothiocyanate" and that "dichlorotriazine fluorescein" is a common fluorescent label. Support for the amendments to the paragraphs on page 23 can be found in figures 5 and 6. Support for the amendment to the paragraph on page 28 can be found in Table 1 on the same page. Therefore, no new matter is added.

A Sequence Listing on paper and in computer readable form was prepared in accordance with 37 C.F.R. §§1.821 to 1.825, and is submitted herewith. The Sequence Listing does not include new matter or matter that goes beyond the disclosure of the International Application. The information contained in the computer readable disk was prepared through the use of the software program "FastSeq" and is identical to that of the paper copy of the Sequence Listing.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,

  
Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
60618259 v1